CONSUMER GENOMIC INTERPRETATION LIABILITY: LEGAL DUTIES, CONSUMER PROTECTION AND JUDICIAL PRECEDENTS

1. INTRODUCTION

Consumer genomic interpretation refers to the process by which a commercial laboratory, biotechnology company, healthcare provider, or direct-to-consumer genetic testing service analyses an individual's DNA and communicates information about ancestry, disease susceptibility, inherited disorders, carrier status, drug responses, or other genetic characteristics.

Liability arises when genomic information is inaccurate, misleading, inadequately explained, unlawfully disclosed, or used in a manner that causes foreseeable harm. For example, a company may falsely reassure a consumer that they have no inherited cancer risk, misclassify a genetic variant, or advertise an unvalidated test as medically reliable.

There is no single universally applicable statute entitled the "Consumer Genomic Interpretation Liability Rules." Instead, liability is determined by applicable consumer protection, medical negligence, product liability, privacy, contract, and medical-device laws. In India, the legal framework remains fragmented, and specialist professional guidance highlights concerns about the scientific validity of direct-to-consumer genetic tests and the absence of adequate genetic counselling.

2. LEGAL FRAMEWORK AND GROUNDS OF LIABILITY

A. Negligent interpretation and professional liability

A laboratory or qualified healthcare professional may face liability where a duty of care exists, the applicable standard of care is breached, and the breach causes legally recognisable harm. Examples include incorrect variant classification, failure to communicate a clinically significant finding, failure to recommend appropriate confirmatory testing, and negligent genetic counselling.

Not every inaccurate result automatically establishes negligence. Genomic science involves uncertainty, and liability depends on whether the interpretation and communication were reasonable given the evidence, the intended use of the test, and professional standards at the relevant time.

B. Consumer protection and misleading representations

In India, the Consumer Protection Act, 2019, may apply where a genomic testing service qualifies as a service supplied to a consumer. Depending on the facts, misleading advertisements, deficient services, unfair trade practices, or defective products may support a complaint.

A provider may be exposed to liability if it claims that a test definitively excludes a disease when the test only evaluates selected variants or estimates a probabilistic risk. Clear disclaimers do not necessarily excuse false advertising, negligent performance, or failure to meet mandatory legal obligations.

C. Privacy and confidentiality

Genetic information can reveal sensitive information about both the tested individual and biological relatives. Unauthorised disclosure, secondary commercial use, or inadequate security may trigger applicable privacy and data-protection obligations.

In India, relevant considerations include constitutional privacy jurisprudence and the Digital Personal Data Protection Act, 2023, subject to its operative provisions, applicable rules, and exemptions. Where applicable, the Information Technology Act, 2000, and associated rules may also be relevant.

D. Scientific validity and regulatory compliance

Testing providers should distinguish analytical validity (whether the test accurately detects a variant), clinical validity (whether the variant reliably relates to a condition), and clinical utility (whether the information improves health decisions). These are different requirements.

The Society for Indian Academy of Medical Genetics has discouraged over-the-counter genetic testing for healthcare purposes without appropriate healthcare-professional involvement and pre-test and post-test counselling. This is professional guidance rather than a statute creating automatic civil liability.

3. IMPORTANT JUDICIAL PRECEDENTS

1. Tompkins v. 23andMe, Inc. (2016) — DIRECT CONSUMER-GENOMICS AUTHORITY

The United States Court of Appeals for the Ninth Circuit upheld enforcement of an arbitration provision in the company's online terms of service. The underlying consumer litigation concerned allegations involving misleading health-related representations, warranties, and unfair business practices. The appellate ruling principally addressed the enforceability of arbitration, not whether the alleged genomic interpretations were negligent. It demonstrates the importance of contractual dispute-resolution clauses in consumer genetic testing. <Cite refs={["turn308545search25"]}/>

2. Simmons v. West Covina Medical Clinic (1989) — DIRECT GENETIC-TESTING AUTHORITY

A California appellate court rejected wrongful-birth and wrongful-life claims where the plaintiffs could not establish the required causal connection between the alleged failure to advise about prenatal screening and the resulting harm. The court emphasised the limited detection probability of the test at issue. The case illustrates that proving a breach of professional duty is not sufficient without legally adequate causation. <Cite refs={["turn308545search12"]}/>

3. Pate v. Threlkel (1995) — DIRECT GENETIC DUTY-TO-WARN AUTHORITY

The Florida Supreme Court considered whether a physician treating a patient with a hereditary cancer risk owed a duty to warn the patient's children. It concluded that the physician's duty was discharged by warning the patient, rather than requiring direct notification of the children. The case is relevant to the communication of hereditary risks, although it concerns a clinical relationship rather than a direct-to-consumer testing company. <Cite refs={["turn308545search4"]}/>

4. Safer v. Estate of Pack (1996) — DIRECT GENETIC DUTY-TO-WARN AUTHORITY

A New Jersey appellate court considered whether a physician's duty concerning hereditary disease could extend beyond the patient to identifiable family members at risk. The decision supported a broader approach to warning potentially affected relatives, subject to the circumstances and applicable confidentiality principles. It highlights the tension between genetic confidentiality and preventing foreseeable harm to biological relatives. <Cite refs={["turn308545search9"]}/>

5. Puttaswamy v. Union of India (2017) — ANALOGOUS CONSTITUTIONAL AUTHORITY

The Supreme Court of India recognised privacy as a fundamental right, including informational privacy and decisional autonomy. The judgment provides a constitutional foundation for challenging unjustified collection, disclosure, or exploitation of genetic information. It did not specifically determine liability for consumer genomic interpretation.

6. Indian Medical Association v. V.P. Shantha (1995) — ANALOGOUS CONSUMER-PROTECTION AUTHORITY

The Supreme Court of India examined when medical services fall within consumer-protection legislation. The decision is relevant when determining whether paid genomic interpretation or associated clinical services may be treated as consumer services. Its application depends on the nature of the service and the statutory framework governing the dispute.

7. Spring Meadows Hospital v. Harjol Ahluwalia (1998) — ANALOGOUS MEDICAL-NEGLIGENCE AUTHORITY

The Supreme Court of India addressed medical negligence and consumer remedies arising from deficient healthcare. Its principles may assist in evaluating professional failures connected with genetic interpretation, counselling, or clinical follow-up, where the necessary duty, breach, causation, and loss can be established.

4. COMPLIANCE REQUIREMENTS AND REMEDIES

Consumer genomic testing providers should adopt the following safeguards:

Scientific validation: Maintain evidence supporting analytical accuracy and the clinical relevance of reported variants.

Transparent reporting: Explain uncertainty, limitations, false-negative risks, and the difference between predisposition and diagnosis.

Informed consent: Explain the test's purpose, potential findings, data use, and relevant implications before testing.

Professional counselling: Provide access to qualified genetic professionals for medically significant findings.

Quality assurance: Maintain validated laboratory procedures, quality-control records, and documented interpretation protocols.

Privacy protection: Establish lawful data-processing arrangements, access controls, security safeguards, and clear retention and deletion policies.

Complaint handling: Preserve test records, issue corrected reports when necessary, investigate complaints, and provide appropriate refunds or other remedies where legally justified.

Depending on the facts and jurisdiction, an affected consumer may seek compensation, refund, correction of misleading claims, regulatory intervention, or other remedies available under consumer, contract, negligence, privacy, and product-liability law.

5. CONCLUSION

Consumer genomic interpretation liability requires a careful assessment of scientific reliability, professional responsibility, consumer expectations, and the harm caused by an inaccurate or misleading result. Tompkins illustrates contractual issues in direct-to-consumer genomics, while Simmons, Pate, and Safer illuminate causation and duties arising from hereditary information. Indian constitutional and consumer-protection precedents provide additional safeguards, although they do not establish a complete genomic-liability code. Effective regulation should combine scientifically validated testing, transparent reporting, appropriate counselling, privacy protection, and accessible remedies for consumers harmed by negligent or deceptive genomic services.